Clinical Trials Update: May 16, 2005
Healthy Patient Studies Respiratory Syncytial Virus (RSV) Infection Atherosclerosis
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
Healthy Patient Studies
Researchers at the University of Kentucky Chandler Medical Center Metabolic Research Group are conducting a medical study to evaluate an investigational drug to see if it will lower the risk of heart attack or stroke.
Qualifications for this study include men who must be 55 years or older and women who must be 65 years or older. No candidate for the study should have a history of heart attack or stroke.
The research site is in Lexington, Ky.
Respiratory Syncytial Virus (RSV) Infection
Primary Physicians Research is currently conducting a clinical trial of an investigational intranasal vaccine to protect against these respiratory syncytial viruses.
Participants must be healthy adults between the ages of 18 and 40 years of age who cannot have had close contact with children under 2 years of age. They also must have a history of asthma or have smoked in the past 5 years.
The research site is in Pittsburgh, Pa.
Atherosclerosis is a slowly progressive disease where there is accumulation of cholesterol within the blood vessel wall.
This ETC-642 study drug may mimic good cholesterol" (HDL-C) and may reduce the size of these atherosclerotic lesions."
Qualifications for participation include a willingness to be able to complete all studies visits and procedures; being between 30 and 80 years old; having HDL cholesterol between 20 and 60 mg/dL; having a history of vascular disease; and giving written informed consent.
Research sites located throughout the United States.
Copyright 2005 CenterWatch. All rights reserved.